BackCelularity- Warrants (16/07/2026) Overview

Celularity- Warrants (16/07/2026) Total Revenue

Celularity- Warrants (16/07/2026)'s total revenue is $27M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$4.10M
77.37% YoY

As of Dec 2025

Annual Revenue (TTM)

$26.55M
51.03% YoY

Trailing 12 months ending Dec 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Celularity- Warrants (16/07/2026) (CELUW) FAQ

Celularity- Warrants (16/07/2026)'s total revenue stands at $27M as of December 2025. That compares with $54M in the prior-year period — down 51.0% year over year. That is below the Healthcare sector average of $110B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Celularity- Warrants (16/07/2026) reported $27M in total revenue versus $54M a year earlier — a 51.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Celularity- Warrants (16/07/2026) sits lower the Healthcare benchmark ($110B) with a total revenue of $27M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $54M in the prior-year period — down 51.0% year over year. Sustained growth in total revenue can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Celularity- Warrants (16/07/2026)'s total revenue evolved across reporting periods, while the comparison chart places CELUW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.